Use of adipsin/complement factor D in the treatment of metabolic related disorders
US6867189B2 · kind B2 · utility
13Cited by
68References
54Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 22, 2002 |
| Grant date | Mar 15, 2005 |
| Priority date | — |
| Expiry date | Oct 20, 2022 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/1709
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the field of metabolic research. Metabolic disorders, such as obesity, are a public health problem that is serious and widespread. Adipsin polypeptides have been identified that are believed to be beneficial in the treatment of metabolic disorders. These compounds should be effective for reducing body mass and for treating metabolic-related diseases and disorders. These metabolic-related diseases and disorders include hyperlipidemias, atherosclerosis, insulin resistance, diabetes, and hypertension.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.